vs
Side-by-side financial comparison of ALBANY INTERNATIONAL CORP (AIN) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.
ALBANY INTERNATIONAL CORP is the larger business by last-quarter revenue ($321.2M vs $168.4M, roughly 1.9× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 12.0%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 1.2%).
Albany International Corp is a global advanced materials and industrial technology company. It operates two core segments: Machine Clothing producing custom engineered fabrics for paper and other industrial manufacturing processes, and Engineered Composites developing high-performance composite components primarily for the aerospace and defense sectors, serving customers across North America, Europe, Asia and other global regions.
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
AIN vs ESPR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $321.2M | $168.4M |
| Net Profit | $13.9M | — |
| Gross Margin | 31.1% | — |
| Operating Margin | 9.3% | 50.6% |
| Net Margin | 4.3% | — |
| Revenue YoY | 12.0% | 143.7% |
| Net Profit YoY | -21.5% | — |
| EPS (diluted) | $0.56 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $321.2M | $168.4M | ||
| Q3 25 | $261.4M | $87.3M | ||
| Q2 25 | $311.4M | $82.4M | ||
| Q1 25 | $288.8M | $65.0M | ||
| Q4 24 | $286.9M | $69.1M | ||
| Q3 24 | $298.4M | $51.6M | ||
| Q2 24 | $332.0M | $73.8M | ||
| Q1 24 | $313.3M | $137.7M |
| Q4 25 | $13.9M | — | ||
| Q3 25 | $-97.8M | $-31.3M | ||
| Q2 25 | $9.2M | $-12.7M | ||
| Q1 25 | $17.4M | $-40.5M | ||
| Q4 24 | $17.7M | — | ||
| Q3 24 | $18.0M | $-29.5M | ||
| Q2 24 | $24.6M | $-61.9M | ||
| Q1 24 | $27.3M | $61.0M |
| Q4 25 | 31.1% | — | ||
| Q3 25 | -19.1% | — | ||
| Q2 25 | 31.3% | — | ||
| Q1 25 | 33.4% | — | ||
| Q4 24 | 31.5% | — | ||
| Q3 24 | 30.3% | — | ||
| Q2 24 | 33.9% | — | ||
| Q1 24 | 34.7% | — |
| Q4 25 | 9.3% | 50.6% | ||
| Q3 25 | -44.6% | -11.4% | ||
| Q2 25 | 7.2% | 8.6% | ||
| Q1 25 | 9.8% | -34.0% | ||
| Q4 24 | 8.5% | -6.4% | ||
| Q3 24 | 8.4% | -31.0% | ||
| Q2 24 | 12.9% | 3.5% | ||
| Q1 24 | 12.4% | 52.5% |
| Q4 25 | 4.3% | — | ||
| Q3 25 | -37.4% | -35.9% | ||
| Q2 25 | 2.9% | -15.4% | ||
| Q1 25 | 6.0% | -62.2% | ||
| Q4 24 | 6.2% | — | ||
| Q3 24 | 6.0% | -57.2% | ||
| Q2 24 | 7.4% | -83.9% | ||
| Q1 24 | 8.7% | 44.3% |
| Q4 25 | $0.56 | $0.32 | ||
| Q3 25 | $-3.37 | $-0.16 | ||
| Q2 25 | $0.31 | $-0.06 | ||
| Q1 25 | $0.56 | $-0.21 | ||
| Q4 24 | $0.57 | $-0.14 | ||
| Q3 24 | $0.57 | $-0.15 | ||
| Q2 24 | $0.79 | $-0.33 | ||
| Q1 24 | $0.87 | $0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $112.3M | $167.9M |
| Total DebtLower is stronger | $455.7M | — |
| Stockholders' EquityBook value | $726.2M | $-302.0M |
| Total Assets | $1.7B | $465.9M |
| Debt / EquityLower = less leverage | 0.63× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $112.3M | $167.9M | ||
| Q3 25 | $108.3M | $92.4M | ||
| Q2 25 | $106.7M | $86.1M | ||
| Q1 25 | $119.4M | $114.6M | ||
| Q4 24 | $115.3M | $144.8M | ||
| Q3 24 | $127.2M | $144.7M | ||
| Q2 24 | $116.4M | $189.3M | ||
| Q1 24 | $125.4M | $226.6M |
| Q4 25 | $455.7M | — | ||
| Q3 25 | $480.6M | — | ||
| Q2 25 | $444.7M | — | ||
| Q1 25 | $416.4M | — | ||
| Q4 24 | $318.5M | — | ||
| Q3 24 | $362.2M | — | ||
| Q2 24 | $377.1M | — | ||
| Q1 24 | $439.1M | — |
| Q4 25 | $726.2M | $-302.0M | ||
| Q3 25 | $739.3M | $-451.4M | ||
| Q2 25 | $888.6M | $-433.5M | ||
| Q1 25 | $900.0M | $-426.2M | ||
| Q4 24 | $943.5M | $-388.7M | ||
| Q3 24 | $991.0M | $-370.2M | ||
| Q2 24 | $967.5M | $-344.2M | ||
| Q1 24 | $967.5M | $-294.3M |
| Q4 25 | $1.7B | $465.9M | ||
| Q3 25 | $1.7B | $364.0M | ||
| Q2 25 | $1.7B | $347.1M | ||
| Q1 25 | $1.7B | $324.0M | ||
| Q4 24 | $1.6B | $343.8M | ||
| Q3 24 | $1.8B | $314.1M | ||
| Q2 24 | $1.8B | $352.3M | ||
| Q1 24 | $1.8B | $373.1M |
| Q4 25 | 0.63× | — | ||
| Q3 25 | 0.65× | — | ||
| Q2 25 | 0.50× | — | ||
| Q1 25 | 0.46× | — | ||
| Q4 24 | 0.34× | — | ||
| Q3 24 | 0.37× | — | ||
| Q2 24 | 0.39× | — | ||
| Q1 24 | 0.45× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $73.7M | $45.2M |
| Free Cash FlowOCF − Capex | $51.4M | — |
| FCF MarginFCF / Revenue | 16.0% | — |
| Capex IntensityCapex / Revenue | 6.9% | 0.0% |
| Cash ConversionOCF / Net Profit | 5.31× | — |
| TTM Free Cash FlowTrailing 4 quarters | $82.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $73.7M | $45.2M | ||
| Q3 25 | $43.9M | $-4.3M | ||
| Q2 25 | $32.7M | $-31.4M | ||
| Q1 25 | $2.1M | $-22.6M | ||
| Q4 24 | $78.5M | $-35.0M | ||
| Q3 24 | $47.0M | $-35.3M | ||
| Q2 24 | $83.4M | $-7.2M | ||
| Q1 24 | $9.6M | $53.8M |
| Q4 25 | $51.4M | — | ||
| Q3 25 | $25.9M | — | ||
| Q2 25 | $18.8M | — | ||
| Q1 25 | $-13.5M | — | ||
| Q4 24 | $60.2M | — | ||
| Q3 24 | $31.6M | $-35.5M | ||
| Q2 24 | $63.6M | $-7.3M | ||
| Q1 24 | $-17.3M | $53.8M |
| Q4 25 | 16.0% | — | ||
| Q3 25 | 9.9% | — | ||
| Q2 25 | 6.0% | — | ||
| Q1 25 | -4.7% | — | ||
| Q4 24 | 21.0% | — | ||
| Q3 24 | 10.6% | -68.7% | ||
| Q2 24 | 19.2% | -9.9% | ||
| Q1 24 | -5.5% | 39.0% |
| Q4 25 | 6.9% | 0.0% | ||
| Q3 25 | 6.9% | 0.0% | ||
| Q2 25 | 4.5% | 0.0% | ||
| Q1 25 | 5.4% | 0.0% | ||
| Q4 24 | 6.4% | 0.0% | ||
| Q3 24 | 5.2% | 0.3% | ||
| Q2 24 | 6.0% | 0.1% | ||
| Q1 24 | 8.6% | 0.1% |
| Q4 25 | 5.31× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 3.56× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 4.44× | — | ||
| Q3 24 | 2.61× | — | ||
| Q2 24 | 3.39× | — | ||
| Q1 24 | 0.35× | 0.88× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AIN
| Transferred At Point In Time | $176.5M | 55% |
| Engineered Composites Other | $99.3M | 31% |
| Engineered Composites ASC | $44.5M | 14% |
| Transferred Over Time | $1.0M | 0% |
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
